 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

This is a Bullish indicator signaling BHC's price could rise from here. Traders may explore going long the stock or buying call options...

Bausch Health Companies (BHC, $6.9) Moving Average Convergence Divergence (MACD) Histogram turned positive on November 17, 2023

This is a Bearish indicator signaling BHC's price could decline from here. Traders may explore shorting the stock or put options...

Bausch Health Companies (BHC, $6.56) Moving Average Convergence Divergence (MACD) Histogram turned negative on November 16, 2023

Bausch Health Companies (BHC, $6.94) Moving Average Convergence Divergence (MACD) Histogram turned positive on November 15, 2023

This is a signal that BHC's price trend could be reversing, and it may be an opportunity to buy the stock or explore call options...

Bausch Health Companies (BHC, $6.53) Stochastic Oscillator left the oversold zone on November 13, 2023

Bausch Health Companies (BHC, $6.53) Moving Average Convergence Divergence (MACD) Histogram turned negative on November 13, 2023

This indicator may be signaling that BHC's price has further to drop, since it moved below its price 14 days ago. Traders may consider selling the stock, shorting the stock, or exploring put options...

Bausch Health Companies (BHC, $6.53) entered Downtrend as Momentum indicator drops below 0 level on Nov 13, 2023

This corrects and replaces the release that was disseminated earlier todayLack of OHE-specific diagnostic code in hospitals may increase risk of additional cost, length of hospitalization and...

CORRECTION BY SOURCE: The Absence of an Overt Hepatic Encephalopathy (OHE)-Specific Diagnosis Code May Result in Increased OHE-Related Length of Stay and Hospitalization-Related Costs Due to OHE Rate Underestimation, According to New Analysis

Lack of OHE-specific diagnostic code in hospitals may increase risk of additional cost, length of hospitalization and additional burdens for patients compared to those with a previous primary OHE...

The Absence of an Overt Hepatic Encephalopathy (OHE)-Specific Diagnosis Code May Result in Increased OHE-Related Length of Stay and Hospitalization-Related Costs Due to OHE Rate Underestimation, According to New Analysis

Company Introduces Multimedia Resources to Bring Awareness of SADLAVAL, QC / ACCESSWIRE / November 8, 2023 / As daylight saving time concluded for much of the US on November 5, and as the seasons...

As Daylight Saving Time Comes to a Close, Bausch Health Champions Mental Health with a Spotlight on Preventing Seasonal Affective Disorder (SAD)

Piper Sandler analyst David Amsellem reiterated a Hold rating on Bausch Health Companies (BHC Research Report) today and set a price target of $7...

Piper Sandler Sticks to Their Hold Rating for Bausch Health Companies (BHC)

Bausch Health Cos., Inc. engages in the development, manufacture and market of a range of branded, generic and branded generic pharmaceuticals, medical devices and over-the-counter products. It operates through the following segments: Salix, International, Solta Medical, Diversified Products, and Bausch + Lomb. The Salix segment consists of sales in the U.S. of GI products. Sales of the Xifaxan product line. The International segment comprises of sales, with the exception of sales of Bausch + Lomb products and Solta aesthetic medical devices, outside the U.S and Puerto Rico of branded pharmaceutical products, branded generic pharmaceutical and OTC products. The Solta Medical segment refer to global sales of Solta Medical aesthetic medical devices. The Diversified Products segment covers sales in the U.S. of pharmaceutical products in the areas of neurology and certain other therapeutic classes, generic products, ortho dermatologics, and dentistry products. The Bausch + Lomb segment are global sales of Bausch + Lomb vision care, surgical and ophthalmic pharmaceuticals products. The company was founded on March 29, 1994 and is headquartered in Laval, Canada.

Watchers	42,437
52-Wk Low	$5.57
52-Wk High	$10.23

Market Cap	$3.5B
Volume (M)	1.44M
52-Wk High	$10.23
52-Wk Low	$5.57

BHC Bausch Health Companies Inc

About

Feed

News

Sentiment

Earnings

Fundamentals